However, the key downstream molecular targets and cell biological processes mediating the oncogenic activity of FGFR2–MEK–ERK signaling in FGFR2 + ICC remain to be defined. This evidence concerns the gene MAP2K7 and intrahepatic cholangiocarcinoma.